The latest edition of the PD(L)anner looks at clinical, regulatory, and commercial milestones in the field of PD-(L)1 inhibitors since we released our last report in September 2022. A major focus of this issue is combinations of inhibitors of PD-(L)1 and novel immuno-oncology mechanisms.
You can also listen to our podcast that accompanies this edition in which Jacob Plieth talks through some of the highlights with Bertrand Delsuc, publisher of BioTech Radar.